Preferred Label : 4-Aminopyridine;

MeSH definition : One of the POTASSIUM CHANNEL BLOCKERS, with secondary effect on calcium currents, which is used mainly as a research tool and to characterize channel subtypes.; One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.;

MeSH synonym : pymadine; 4 aminopyridine; Dalfampridine;

MeSH hyponym : VMI-103; 4-Aminopyridine sustained release; VMI 103; VMI103; 4 Aminopyridine Sustained Release; Sustained Release, 4-Aminopyridine; Fampridine-SR; Fampridine SR;

MeSH CAS label : 4-Pyridinamine;

MeSH Related Number : 504-24-5 (4-Aminopyridine);

Registry Number MeSH : 504-24-5;

Wikipedia link : https://en.wikipedia.org/wiki/4-Aminopyridine;

Codes EINECS : 207-987-9;

Is substance : O;

UNII : BH3B64OKL9;

InChIKey : NUKYPUAOHBNCPY-UHFFFAOYSA-N;

Details


Main resources

You can consult :

One of the POTASSIUM CHANNEL BLOCKERS, with secondary effect on calcium currents, which is used mainly as a research tool and to characterize channel subtypes.
One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.

https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
4-Aminopyridine
4-Aminopyridine
multiple sclerosis
adult
gait disorders, neurologic
Persons with Disabilities
drugs, generic
administration, oral
fampridine
potassium channel blockers
potassium channel blockers
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.has-sante.fr/portail/jcms/c_2883451/fr/fampyra
https://www.has-sante.fr/portail/jcms/c_2883451/fr/fampyra-fampridine-bloqueur-des-canaux-potassiques-voltage-dependants
2018
false
France
French
evaluation of the transparency committee
guidelines for drug use
administration, oral
Delayed-Action preparations
insurance, health, reimbursement
4-Aminopyridine
Persons with Disabilities
multiple sclerosis
adult
fampridine
gait disorders, neurologic
treatment outcome
pharmacovigilance
walking

---
http://www.has-sante.fr/portail/jcms/c_2757143/fr/firdapse
2017
false
false
France
French
administration, oral
potassium channel blockers
treatment outcome
4-Aminopyridine
insurance, health, reimbursement
amifampridine
adult
lambert-eaton myasthenic syndrome
evaluation of the transparency committee
Amifampridine
Amifampridine

---
http://www.has-sante.fr/portail/jcms/c_2034297/fr/fampyra
http://www.has-sante.fr/portail/jcms/c_1244156/fampyra
2015
false
France
French
evaluation of the transparency committee
administration, oral
Delayed-Action preparations
insurance, health, reimbursement
4-Aminopyridine
Persons with Disabilities
multiple sclerosis
adult
fampridine
gait disorders, neurologic
4-Aminopyridine
treatment outcome
clinical trials, phase iii as topic
randomized controlled trials as topic
pharmacovigilance
walking

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=170712&nom=Amino-2+méthyl-4+pyridine
Canada
toxicological data sheet
pyridine
4-Aminopyridine

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=152942&nom=Amino-4+pyridine
Canada
toxicological data sheet
4-Aminopyridine
pyridine

---
http://www.meddispar.fr/Medicaments/FAMPYRA-10-B-28/%28type%29/letter/%28value%29/F/%28cip%29/3400921939545
http://www.meddispar.fr/Medicaments/FAMPYRA-10-B-56/(type)/letter/(value)/F/(cip)/3400921939606
2013
France
French
administration, oral
drug prescriptions
legislation, drug
fampridine
4-Aminopyridine
drug information

---
https://www.ema.europa.eu/medicines/human/EPAR/Fampyra
2012
United Kingdom
French
English
summary of product characteristics
package leaflet
drug evaluation
syndication feed
4-Aminopyridine
4-Aminopyridine
drug approval
treatment outcome
administration, oral
adult
multiple sclerosis
potassium channel blockers
potassium channel blockers
fampridine
Delayed-Action preparations
Persons with Disabilities
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00060
2012
false
false
false
Canada
fampridine
Product containing precisely fampridine 10 milligram/1 each prolonged-release oral tablet (clinical drug)
4-Aminopyridine
drug information

---
http://www.has-sante.fr/portail/jcms/c_1269678/fampyra-fampridine-bloqueur-des-canaux-potassiques-voltage-dependants
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-07/fampyra_11042012_avis_ct_11904.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-05/fampyra_11042012_avis_ct11904.pdf
2012
France
French
guidelines for drug use
evaluation of the transparency committee
4-Aminopyridine
potassium channel blockers
gait disorders, neurologic
multiple sclerosis
fampridine
adult
Persons with Disabilities
treatment outcome
administration, oral
Delayed-Action preparations
insurance, health, reimbursement
4-Aminopyridine
potassium channel blockers
clinical trials, phase ii as topic
clinical trials, phase iii as topic
randomized controlled trials as topic
seizures
risk assessment

---
http://www.cochrane.org/fr/CD003279
2011
United Kingdom
France
French
meta-analysis
treatment outcome
lambert-eaton myasthenic syndrome
4-Aminopyridine
immunoglobulins, intravenous
potassium channel blockers
french abstract

---
http://www.has-sante.fr/portail/jcms/c_962465/firdapse
2010
false
France
French
guidelines for drug use
administration, oral
potassium channel blockers
treatment outcome
4-Aminopyridine
insurance, health, reimbursement
amifampridine
adult
lambert-eaton myasthenic syndrome
evaluation of the transparency committee
Amifampridine
Amifampridine

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.